Efficacy of Doxorubicin After Progression on Carboplatin and Paclitaxel in Advanced or Recurrent Endometrial Cancer: a Retrospective Analysis of Patients Treated at the Brazilian National Cancer Institute (INCA)

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2018 Feb 2

PMID 29387971

Citations 5

Authors

Emeline Moreira

Eduardo Paulino

Alvaro Henrique Ingles Garces

Mariane S Fontes Dias

Marcos Saramago

Flora de Moraes Lino da Silva

Luiz Claudio Santos Thuler

Andreia Cristina de Melo

Affiliations

Soon will be listed here.

Abstract

The treatment of endometrial cancer (EC) is challenging. There is no standard of care for patients who progressed after carboplatin and paclitaxel (CT) and all available drugs show a small response and poor long-term survival in this scenario. The objective of this study was to evaluate the efficacy and toxicity profile of palliative doxorubicin after progression to CT therapy in advanced or recurrent EC. A retrospective review of the Brazilian National Cancer Institute database between 2009 and 2013 was performed, and all patients with recurrent and advanced EC treated with palliative doxorubicin after progression on CT were included. Progression-free survival (PFS), overall survival (OS), objective response rates as well as toxicity were evaluated. A total of 33 patients were enrolled, with a median age of 65.7 years. Objective responses were documented in 12.1% (3.0% of complete responses and 9.1% of partial responses). The median PFS was 4.4 months, and the median OS was 8.1 months for patients exposed to doxorubicin. The most common adverse event was anemia observed in 60.6% of patients. This retrospective study suggests that doxorubicin has a modest activity in patients with advanced or recurrent EC after treatment with CT.

Citing Articles

Lenvatinib Plus Pembrolizumab versus Doxorubicin for Advanced or Recurrent Endometrial Cancer with Short Treatment-Free Intervals Following First-Line Carboplatin Plus Paclitaxel.

Wang S, Chen H, Sun L, Shih Y, Lu T, Chen Y J Clin Med. 2024; 13(19).

PMID: 39407730 PMC: 11476733. DOI: 10.3390/jcm13195670.

Acyl Urea Compounds Therapeutics and its Inhibition for Cancers in Women: A Review.

Kumari P, Mishra R, Mazumder R, Mazumder A Anticancer Agents Med Chem. 2024; 25(2):86-98.

PMID: 39318218 DOI: 10.2174/0118715206330232240913100744.

A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer.

Han S, Oza A, Colombo N, Oaknin A, Raspagliesi F, Wenham R Gynecol Oncol. 2023; 178:110-118.

PMID: 37839313 PMC: 11100409. DOI: 10.1016/j.ygyno.2023.09.013.

Looking beyond carboplatin and paclitaxel for the treatment of advanced/recurrent endometrial cancer.

Rubinstein M, Shen S, Monk B, Tan D, Nogueira-Rodrigues A, Aoki D Gynecol Oncol. 2022; 167(3):540-546.

PMID: 36280455 PMC: 10373231. DOI: 10.1016/j.ygyno.2022.10.012.

Pharmacological Treatment of Advanced, Persistent or Metastatic Endometrial Cancer: State of the Art and Perspectives of Clinical Research for the Special Issue "Diagnosis and Management of Endometrial Cancer".

Gadducci A, Cosio S Cancers (Basel). 2021; 13(24).

PMID: 34944775 PMC: 8699529. DOI: 10.3390/cancers13246155.

References

Oza A, Elit L, Tsao M, Kamel-Reid S, Biagi J, Provencher D . Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol. 2011; 29(24):3278-85. PMC: 3158598. DOI: 10.1200/JCO.2010.34.1578. View

Escobar P, Markman M, Zanotti K, Webster K, Belinson J . Phase 2 trial of pegylated liposomal doxorubicin in advanced endometrial cancer. J Cancer Res Clin Oncol. 2003; 129(11):651-4. DOI: 10.1007/s00432-003-0497-8. View

Creutzberg C, Nout R . The role of radiotherapy in endometrial cancer: current evidence and trends. Curr Oncol Rep. 2011; 13(6):472-8. PMC: 3212694. DOI: 10.1007/s11912-011-0191-y. View

Colombo N, Preti E, Landoni F, Carinelli S, Colombo A, Marini C . Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011; 22 Suppl 6:vi35-9. DOI: 10.1093/annonc/mdr374. View

Aghajanian C, Sill M, Darcy K, Greer B, McMeekin D, Rose P . Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2011; 29(16):2259-65. PMC: 3107744. DOI: 10.1200/JCO.2010.32.6397. View

Ueda Y, Miyake T, Egawa-Takata T, Miyatake T, Matsuzaki S, Yokoyama T . Second-line chemotherapy for advanced or recurrent endometrial carcinoma previously treated with paclitaxel and carboplatin, with or without epirubicin. Cancer Chemother Pharmacol. 2010; 67(4):829-35. PMC: 3064891. DOI: 10.1007/s00280-010-1384-z. View

Muggia F, Blessing J, Sorosky J, Reid G . Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2002; 20(9):2360-4. DOI: 10.1200/JCO.2002.08.171. View

Koh W, Greer B, Abu-Rustum N, Apte S, Campos S, Cho K . Uterine Sarcoma, Version 1.2016: Featured Updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2015; 13(11):1321-31. DOI: 10.6004/jnccn.2015.0162. View

Siegel R, Miller K, Jemal A . Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7-30. DOI: 10.3322/caac.21387. View

10.

Kar S, Pradhan H, Mohanta G . Concept of essential medicines and rational use in public health. Indian J Community Med. 2010; 35(1):10-3. PMC: 2888334. DOI: 10.4103/0970-0218.62546. View

11.

Ott P, Bang Y, Berton-Rigaud D, Elez E, Pishvaian M, Rugo H . Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. J Clin Oncol. 2017; 35(22):2535-2541. DOI: 10.1200/JCO.2017.72.5952. View

12.

Fleming G . Second-Line Therapy for Endometrial Cancer: The Need for Better Options. J Clin Oncol. 2015; 33(31):3535-40. DOI: 10.1200/JCO.2015.61.7225. View

13.

Ray-Coquard I, Favier L, Weber B, Roemer-Becuwe C, Bougnoux P, Fabbro M . Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO. Br J Cancer. 2013; 108(9):1771-7. PMC: 3658508. DOI: 10.1038/bjc.2013.183. View

14.

Nagao S, Nishio S, Michimae H, Tanabe H, Okada S, Otsuki T . Applicability of the concept of "platinum sensitivity" to recurrent endometrial cancer: the SGSG-012/GOTIC-004/Intergroup study. Gynecol Oncol. 2013; 131(3):567-73. DOI: 10.1016/j.ygyno.2013.09.021. View

15.

Kandoth C, Schultz N, Cherniack A, Akbani R, Liu Y, Shen H . Integrated genomic characterization of endometrial carcinoma. Nature. 2013; 497(7447):67-73. PMC: 3704730. DOI: 10.1038/nature12113. View

16.

Dizon D, Blessing J, McMeekin D, Sharma S, DiSilvestro P, Alvarez R . Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-P. J Clin Oncol. 2009; 27(19):3104-8. PMC: 2716935. DOI: 10.1200/JCO.2008.20.6995. View

17.

Moxley K, McMeekin D . Endometrial carcinoma: a review of chemotherapy, drug resistance, and the search for new agents. Oncologist. 2010; 15(10):1026-33. PMC: 3227900. DOI: 10.1634/theoncologist.2010-0087. View

18.

Makker V, Hensley M, Zhou Q, Iasonos A, Aghajanian C . Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009. Int J Gynecol Cancer. 2013; 23(5):929-34. PMC: 3694716. DOI: 10.1097/IGC.0b013e3182915c20. View

19.

Jafari Shobeiri M, Mostafa Gharabaghi P, Esmaeili H, Ouladsahebmadarek E, Mehrzad-Sadagiani M . Fertility sparing treatment in young patients with early endometrial adenocarcinoma: case series. Pak J Med Sci. 2013; 29(2):651-5. PMC: 3809239. DOI: 10.12669/pjms.292.3280. View

20.

Klopp A, Jhingran A, Ramondetta L, Lu K, Gershenson D, Eifel P . Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation. Gynecol Oncol. 2009; 115(1):6-11. DOI: 10.1016/j.ygyno.2009.06.035. View